New drug targets in the signaling pathways activated by antidepressants

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 6, 2005, Pages 1010-1016

  Páez Pereda, Marcelo ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Affectis Pharmaceutical AG   (Germany)

Author keywords

Antidepressants; Corticosteroids; Monoamines; Signal transduction

Indexed keywords

ANTIDEPRESSANT AGENT; ARGIPRESSIN; CALCIUM; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MIFEPRISTONE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BIOINFORMATICS; CALCIUM SIGNALING; CLINICAL FEATURE; CORTICOSTEROID RELEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MONOAMINE METABOLISM; NONHUMAN; PHARMACOGENOMICS; PROMOTER REGION; SEROTONIN UPTAKE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

EID: 23144443897     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.03.017     Document Type: Review

References (51)

1. L. Arborelius, M.J. Owens, P.M. Plotsky, and C.B. Nemeroff The role of corticotropin-releasing factor in depression and anxiety disorders J. Endocrinol. 160 1999 1 12
2. C. Beasley, D. Cotter, and I. Everall An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder Schizophr. Res. 58 2002 63 67
3. J.K. Belanoff, B.H. Flores, M. Kalezhan, B. Sund, and A.F. Schatzberg Rapid reversal of psychotic depression using mifepristone J. Clin. Psychopharmacol. 21 2001 516 521
4. J.D. Brown, and R.T. Moon Wnt signaling: why is everything so negative? Curr. Opin. Cell Biol. 10 1998 182 187
5. A.C. Chen, Y. Shirayama, K.H. Shin, R.L. Neve, and R.S. Duman Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect Biol. Psychiatry 49 2001 753 762
6. A.C. Conti, J.F. Cryan, A. Dalvi, I. Lucki, and J.A. Blendy cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs J. Neurosci. 22 2002 3262 3268
7. C. D'Sa, and R.S. Duman Antidepressants and neuroplasticity Bipolar Disord. 4 2002 183 194
8. T.D. Gould, and H.K. Manji The Wnt signaling pathway in bipolar disorder Neuroscientist 8 2002 497 511
9. P. Greengard, P.B. Allen, and A.C. Nairn Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade Neuron 23 1999 435 447
10. G. Griebel, J. Simiand, C. Serradeil-Le Gal, J. Wagnon, M. Pascal, B. Scatton, J.P. Maffrand, and P. Soubrie Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders Proc. Natl. Acad. Sci. U. S. A. 99 2002 6370 6375
11. I. Heuser, A. Yassouridis, and F. Holsboer The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders J. Psychiatr. Res. 28 1994 341 356
12. F. Holsboer The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety J. Psychiatr. Res. 33 1999 181 214
13. F. Holsboer The corticosteroid receptor hypothesis of depression Neuropsychopharmacology 23 2000 477 501
14. F. Holsboer Antidepressant drug discovery in the postgenomic era World J. Biol. Psychiatry 1 2001 541 549
15. F. Holsboer Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy J. Affect. Disord. 62 2001 77 91
16. F. Holsboer, and N. Barden Antidepressants and hypothalamic-pituitary- adrenocortical regulation Endocr. Rev. 17 1996 187 205
17. D.K. Kim, S.W. Lim, S. Lee, S.E. Sohn, S. Kim, C.G. Hahn, and B.J. Carroll Serotonin transporter gene polymorphism and antidepressant response NeuroReport 11 2000 215 219
18. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. U. S. A. 93 1996 8455 8459
19. J. Landgrebe, G. Welzl, T. Metz, M.M. van Gaalen, H. Ropers, W. Wurst, and F. Holsboer Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling J. Psychiatr. Res. 36 2002 119 129
20. C.J. Lauer, W. Schreiber, S. Modell, F. Holsboer, and J.C. Krieg The Munich vulnerability study on affective disorders: overview of the cross-sectional observations at index investigation J. Psychiatr. Res. 32 1998 393 401
21. R.C. Malenka, and R.A. Nicoll Long-term potentiation-a decade of progress? Science 285 1999 1870 1874
22. M.B. Muller, M.E. Keck, E.B. Binder, A.E. Kresse, T.P. Hagemeyer, R. Landgraf, F. Holsboer, and M. Uhr ABCB1 (MDR1)-type p-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary- adrenocortical system: implications for affective disorder Neuropsychopharmacology 28 2003 1991 1999
23. M.B. Muller, S. Zimmermann, I. Sillaber, T.P. Hagemeyer, J.M. Deussing, P. Timpl, M.S. Kormann, S.K. Droste, R. Kuhn, J.M. Reul, F. Holsboer, and W. Wurst Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress Nat. Neurosci. 6 2003 1100 1107
24. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neurobiology of depression Neuron 34 2002 13 25
25. E.J. Nestler, E. Gould, H. Manji, M. Buncan, R.S. Duman, H.K. Greshenfeld, R. Hen, S. Koester, I. Lederhendler, M. Meaney, T. Robbins, L. Winsky, and S. Zalcman Preclinical models: status of basic research in depression Biol. Psychiatry 52 2002 503 528
26. M. Nibuya, E.J. Nestler, and R.S. Duman Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus J. Neurosci. 16 1996 2365 2372
27. R.X. Petrie, I.C. Reid, and C.A. Stewart The N-methyl-d-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review Pharmacol. Ther. 87 2000 11 25
28. M. Popoli, M. Gennarelli, and G. Racagni Modulation of synaptic plasticity by stress and antidepressants Bipolar Disord. 4 2002 166 182
29. J.M. Reul, I. Stec, M. Soder, and F. Holsboer Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system Endocrinology 133 1993 312 320
30. J.M. Reul, M.S. Labeur, D.E. Grigoriadis, E.B. De Souza, and F. Holsboer Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide Neuroendocrinology 60 1994 509 519
31. J.M. Reul, A. Gesing, S. Droste, I.S. Stec, A. Weber, C. Bachmann, A. Bilang-Bleuel, F. Holsboer, and A.C. Linthorst The brain mineralocorticoid receptor: greedy for ligand, mysterious in function Eur. J. Pharmacol. 405 2000 235 249
32. A.D. Roses Genome-based pharmacogenetics and the pharmaceutical industry Nat. Rev., Drug Discov. 1 2002 541 549
33. U. Schmidt, G.M. Wochnik, M.C. Rosenhagen, J.C. Young, F.U. Hartl, F. Holsboer, and T. Rein Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the glucocorticoid receptor J. Biol. Chem. 278 2003 4926 4931
34. A. Serretti, R. Zanardi, C. Cusin, D. Rossini, R. Lilli, C. Lorenzi, E. Lattuada, and E. Smeraldi No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors Psychiatry Res. 104 2001 195 203
35. A. Serretti, R. Zanardi, D. Rossini, C. Cusin, R. Lilli, and E. Smeraldi Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity Mol. Psychiatry 6 2001 586 592
36. A. Serretti, R. Zanardi, C. Cusin, D. Rossini, C. Lorenzi, and E. Smeraldi Tryptophan hydroxylase gene associated with paroxetine antidepressant activity Eur. Neuropsychopharmacol. 11 2001 375 380
37. A. Serretti, R. Lilli, and E. Smeraldi Pharmacogenetics in affective disorders Eur. J. Pharmacol. 438 2002 117 128
38. T.J. Shors, M.R. Foy, S. Levine, and R.F. Thompson Unpredictable and uncontrollable stress impairs neuronal plasticity in the rat hippocampus Brain Res. Bull. 24 1990 637 663
39. E. Smeraldi, R. Zanardi, F. Benedetti, D. Di Bella, J. Perez, and M. Catalano Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine Mol. Psychiatry 3 1998 508 511
40. D. Spengler, R. Rupprecht, L.P. Van, and F. Holsboer Identification and characterization of a 3′,5′-cyclic adenosine monophosphate- responsive element in the human corticotropin-releasing hormone gene promoter Mol. Endocrinol. 6 1992 1931 1941
41. V. Stambolic, L. Ruel, and J.R. Woodgett Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells Curr. Biol. 6 1996 1664 1668
42. C.A. Stewart, and I.C. Reid Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity Psychopharmacology (Berl.) 148 2000 217 223
43. P. Svenningsson, E.T. Tzavara, J.M. Witkin, A.A. Fienberg, G.G. Nomikos, and P. Greengard Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Proc. Natl. Acad. Sci. U. S. A. 99 2002 3182 3187
44. P. Timpl, R. Spanagel, I. Sillaber, A. Kresse, J.M. Reul, G.K. Stalla, V. Blanquet, T. Steckler, F. Holsboer, and W. Wurst Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 Nat. Genet. 19 1998 162 166
45. O.M. Wolkowitz, and V.I. Reus Treatment of depression with antiglucocorticoid drugs Psychosom. Med. 61 1999 698 711
46. M.L. Wong, P. Khatri, J. Licinio, A. Esposito, and P.W. Gold Identification of hypothalamic transcripts upregulated by antidepressants Biochem. Biophys. Res. Commun. 229 1996 275 279
47. M. Yamada, and T. Higuchi Functional genomics and depression research. Beyond the monoamine hypothesis Eur. Neuropsychopharmacol. 12 2002 235 244
48. B.P. Zambrowics, and A.T. Sands Knockouts model the 100 best-selling drugs-will they model the next 100? Nat. Rev., Drug Discov. 2 2003 38 51
49. E. Zeller, H.J. Stief, B. Pflug, and M. Sastre-y-Hernandez Results of a phase II study of the antidepressant effect of rolipram Pharmacopsychiatry 17 1984 188 190
50. A.W. Zobel, A. Yassouridis, R.M. Frieboes, and F. Holsboer Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression Am. J. Psychiatry 156 1999 949 951
51. A.W. Zobel, T. Nickel, H.E. Kunzel, N. Ackl, A. Sonntag, M. Ising, and F. Holsboer Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J. Psychiatr. Res. 34 2000 171 181